The FDA record identifies Roche Molecular System, Inc. as the applicant for P200014, approved on June 18, 2020, with the cobas® EZH2 Mutation Test as the trade name and a somatic gene mutation detection system as the generic name. The approval letter is addressed to a regulatory affairs manager at Roche Molecular Systems, Inc. in Pleasanton, California, and the SSED lists the same Pleasanton address for the applicant. The public documents do not establish a parent company, brand ownership or corporate website for this applicant. [2][4][9]
The approved device and its stated scope
The SSED describes the cobas® EZH2 Mutation Test as a real-time allele-specific PCR test for qualitative detection of single nucleotide mutations Y646N, Y646F or Y646X (Y646H, Y646S or Y646C), A682G and A692V of the EZH2 gene in DNA extracted from formalin fixed paraffin embedded human follicular lymphoma tumor tissue specimens. The approval statement in the FDA record gives the same mutation set and specimen type, and ties intended use to identification of follicular lymphoma patients with an EZH2 mutation for treatment with TAZVERIK (tazemetostat) in accordance with approved therapeutic product labeling. [2][4]
The SSED interpretation table lists three reported outcomes: Mutation Detected, covering the named mutations with the note that more than one mutation may be present; No Mutation Detected; and Invalid, for which the document directs repeat testing of specimens following its retesting section. The table also lists a Failed category. [4]
Regulatory identifiers and classification
FDA records assign the device product code OWD, device class 3, and the advisory committee code PA with the description Pathology. The generic name in the FDA data is Somatic gene mutation detection system, while the SSED states the device generic name as Real-time PCR test. The expedited review flag is recorded as N on both the original approval and the 2026 supplement. [1][2][4]
The approval letter carries PMA number P200014, states the application was filed March 3, 2020, and records amendments dated March 23, 2020 and April 23, 2020. The FDA record gives a decision date of June 18, 2020 under decision code APWD and a Federal Register notice date of June 22, 2020. [2][9]
The 2026 manufacturing supplement
Supplement P200014/S012 is recorded as a 30-Day Notice with supplement type 30-Day Notice and reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. Its applicant-stated objective is to change the manufacturing process for oligonucleotides. The FDA received it September 30, 2026 and decided it October 27, 2026 under decision code OK30. [1]
The supplement record repeats the same trade name, product code OWD, class 3 designation, Pathology advisory committee and Pleasanton address as the original approval. FDA pages for P200014 note that the device has supplements and that the device description, function or indication may have changed, directing readers to the supplements for current information. [1][5][8]
What the supplied collection shows
The supplied collection contains two linked PMA records, both under P200014, with decision counts of one OK30 and one APWD. The smaller record sample of two entries shows the same split: the 2026 supplement under OK30 and the 2020 original under APWD. These counts describe the supplied filings as of the snapshot date and are not measures of total portfolio, sales or safety performance. [1][2]
A Roche eLabDoc product catalog page lists the cobas® EZH2 Mutation Test with a note that it is for in vitro diagnostic use and shows documentation categories including lot, method sheet and safety data sheet, with order information behind a login. The same page lists the cobas z 480 instrument as a related product with catalog numbers. The public documents do not document commercial availability, customers or independent performance results. [6]


